Châtillon, France, July 29, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2025, of its Half-Year Report with the French market authority, “Autorité... Read More

Châtillon, France, July 29, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. The quarterly and half-year financial statements were approved by the Board of Directors on July 29, 2025. Financial Highlights for the Second Quarter Ended June 30, 2025 The... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2025: 210,069 DBV Technologies shares, € 171,301.08. When the liquidity contract with... Read More

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of James Briggs as its Chief Human Resources Officer, succeeding Caroline Daniere. An experienced human capital executive, James will lead key initiatives as DBV transitions from a... Read More

First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings Châtillon, France, June 25, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market:... Read More

Châtillon, France, June 12, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in... Read More

Shareholders approved all proposed resolutions Châtillon, France, June 11, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “ Company ”), held its Combined General Meeting (the “ General Meeting ”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted... Read More

Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 05/30/2025 136,973,697 Total gross of voting rights: 136,973,697 Total net* of voting rights: 136,738,528 * Net... Read More

Châtillon, France, June 03, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “ Company ”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “ Addendum ”) with the French market authority, “Autorité des Marchés Financiers” (“ AMF ”). This Addendum provides an update to the Board of... Read More

Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting Châtillon, France, May 15, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “ Company ”), will hold its Combined General Meeting (the “ General Meeting ”) on June 11, 2025, at 02:00 p.m. CEST (08:00... Read More

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 04/30/2025 136,948,872 Total gross of voting rights: 136,948,872 Total net* of voting rights: 136,762,549 * Net... Read More

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference Châtillon, France, May 5, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York,... Read More

Châtillon, France, April 30, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. Financial Highlights for the First Quarter En ded March 31, 2025 The... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced: The audited financial statements for the year ended December 31, 2024 were approved by the Board of Directors on April 11, 2025, and present no changes... Read More

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants DBV sufficiently funded through the expected Biologics License Application (BLA) submission... Read More

COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Label Extension (OLE) are sufficient to support a Biologics License Application (BLA) for Viaskin peanut patch in children 4 – 7-years-old VITESSE topline results on-track for the fourth quarter of 2025 BLA submission for Viaskin peanut... Read More

Châtillon, France, February 25, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David... Read More

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF Châtillon, France, January 13, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity... Read More

EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12 No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE DBV... Read More

DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025 Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-old Company to host investor... Read More

DBV Technologies: Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 11/30/2024 102,847,501 Total gross of voting rights: 102,847,501 Total net* of voting... Read More

DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, November 11, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American... Read More

DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the... Read More

DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025 VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 European Medicines Agency (EMA) scientific... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, October 24 – 28 th , 2024 in Boston, Massachusetts. This year’s meeting will feature a “Product Theater” on What Defines an Optimal Peanut Allergy Treatment? During this... Read More

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2024 96,501,526 Total gross of voting rights: 96,501,526 Total net* of voting rights: 96,199,467 * Net total = total number of voting rights attached to shares – shares without voting rights Read More

In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin ® Peanut Patch in peanut allergic children ages 4 – 7 years old Topline results of VITESSE data are expected by Q4 2025 Châtillon, France, September 23, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical... Read More

Châtillon, France, September 4, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26 th Annual Global Investment Conference on Monday, September 9, 2024, at 3:00 pm ET, in New York City. A live webcast of the presentation can... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2024, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”).... Read More

VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA’s protocol queries regarding patch wear-time in COMFORT Toddlers DBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company’s... Read More

Châtillon, France, July 29, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30 th , at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update. Interested participants may access this call via the below... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2024: 303,744 DBV Technologies shares, € 62,415.60 When the liquidity contract with ODDO... Read More

Châtillon, France, June 5, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45 th Annual Goldman Sachs Global Healthcare... Read More

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 05/31/2024 96,493,078 Total gross of voting rights: 96,493,078 Total net* of voting rights: 96,236,383 * Net total... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per... Read More

Châtillon, France, May 30, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia,... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per... Read More

Shareholders approved all proposed resolutions Châtillon, France, May 16, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “ Company ”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “ General Meeting ”). The General Meeting was... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 13, 2024... Read More

VITESSE enrollment on track to screen last patient by Q3 2024 Appointment of Robert Pietrusko, PharmD to Chief Regulatory Officer Q1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need,... Read More

Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting Châtillon, France, April 25, 2024- DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “ Company ”), will hold its Combined General... Read More

DBV Technologies - Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 03/31/2024 96,434,369 Total gross of voting rights: 96,434,369 Total net* of voting rights:... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its... Read More

DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Strengthened executive leadership team in preparation for BLA submission Reported cash and cash equivalents of $141 million Montrouge, France, March 7, 2024 - DBV Technologies (Euronext: DBV – ISIN:... Read More

Montrouge, France, March 4, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update. Interested participants may... Read More

Montrouge, France, February 20 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C. A poster presentation by David Fleischer, M.D. of Children’s Hospital Colorado will... Read More

AMF Regulated Information - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF Montrouge, France, January 16, 2024 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF. Under the liquidity contract between DBV Technologies and NATIXIS ODDO BHF,... Read More

Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment. 55.9% of subjects completed the oral food challenge at a cumulative dose of 3,444 mg without meeting stopping criteria. Among treatment-arm subjects from EPITOPE, there were no... Read More

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 10/31/2023 96,288,553 Total gross of voting rights: 96,288,553 Total net* of voting rights: 96,084,083... Read More

DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of... Read More

DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarifying design elements for both the COMFORT Toddlers and COMFORT Children supplemental safety studies. Both supplemental safety studies will have harmonized, simplified protocol language on how the product should be used. The COMFORT Toddlers study will apply the same eligibility criteria as EPITOPE, DBV’s successful Phase 3 efficacy study... Read More

Montrouge, France, October 27, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31 st , at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update. Interested participants may access this call via the... Read More

Montrouge, France, October 16, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of... Read More

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2023 96,253,553 Total gross of voting rights: 96,253,553 Total net* of voting rights:... Read More

Montrouge, France, September 5, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11 th −13 th in New York, NY. Daniel Tassé, Chief Executive Officer, will represent the company in a fireside chat session on... Read More

R eceived feedback from U.S. Food and Drug Administration (FDA) on DBV’s two supplemental safety stud ies in toddlers ( ages 1 – 3 years) and children ( ages 4 – 7 years) . The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 – 3 years) and COMFORT Children (4 – 7 years). COMFORT Toddlers will be a 6-month safety study, consistent with agreement previously reached with FDA on the COMFORT Children safety... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, July 31 st , at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update. Participants may access this event via the below teleconferencing numbers and asking to join the DBV... Read More

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 06/30/2023 96,250,954 Total gross of voting rights: 96,250,954 Total net* of voting rights: 96,100,982 *... Read More

Montrouge, France, July 10, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2023: 149,972 DBV Technologies shares, € 317,981.... Read More

Montrouge, France, June 8, 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data... Read More

DB V Technologies to Participate in Upcoming Investor Conference Montrouge, France, June 06, 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the Goldman Sachs 44 th Annual Global Healthcare Conference taking place on June 12 th – 15 th in Dana Point, CA. Daniel Tassé, Chief Executive Officer, will engage... Read More

Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT TM ) with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut by increasing the peanut dose that... Read More

D BV Technologies to Participate in Upcoming Investor Conference Montrouge, France, May 9, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the JMP Securities Life Sciences Conference taking place May 15-16 in New York, NY. Daniel Tassé, Chief Executive Officer, will make a company presentation on Monday,... Read More

DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter of 2023. The quarterly financial statements were approved by the Board of Directors on May 4, 2023. Financial Highlights for the First Quarter and the Three Months Ended March... Read More

The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint and did not request an additional efficacy study . A dditional safety data will be required to augment the safety data collected from EPITOPE in support of a BLA . Th e new safety study will also generate patch adhesion data and include updated Instructions for Use (IFU). Company reports cash and... Read More

DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions Montrouge, France, April 12, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of... Read More

Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “ General Meeting ”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters... Read More

Montrouge, France, March 13, 2023 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank. About DBV Technologies DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin... Read More

First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois VITESSE is DBV’s Phase 3 clinical study evaluating the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 7 years DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the first patient has been screened in the Company’s VITESSE ( V iaskin Peanut I... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) and the filing of its 2022 Universal Registration Document (“URD”) for the year ended December 31, 2022 with the French market... Read More

DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old DBV had $209.2 million in Cash and Cash Equivalents at December 31, 2022. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the full year 2022. The... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 2, at 5:00 p.m. ET to report full year 2022 financial results and provide a business update. Interested participants may access this call via the below teleconferencing numbers and asking to join... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Scientific meeting, taking place February 24-27 in San Antonio, TX. Two scientific poster presentations have been accepted on efficacy and safety data from subgroups of patients from the... Read More

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the virtual SBV Securities Global Biopharma Conference taking place February 13 – 16, 2023. Daniel Tassé, Chief Executive Officer, will make a company presentation on Thursday, February 16, 2023, as well as participate in one-on-one investor meetings throughout... Read More

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologie s (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2022:... Read More

DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline results anticipated in 1H 2025 Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)... Read More